Research programme: cannabidiol-based therapeutics - KannaLife Sciences

Drug Profile

Research programme: cannabidiol-based therapeutics - KannaLife Sciences

Alternative Names: Cannabinoid-based antioxidants - KannaLife Sciences; Cannabinoid-based neuroprotectants - KannaLife Sciences; KLS-13019

Latest Information Update: 25 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator KannaLife Sciences
  • Class Analgesics; Anti-inflammatories; Benzene derivatives; Cannabinoids; Neuroprotectants; Small molecules
  • Mechanism of Action Antioxidants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Brain injuries; Hepatic encephalopathy; Neuropathic pain

Most Recent Events

  • 22 Sep 2017 KannaLife Sciences has patent protection for cannabidiol-based therapeutics in USA
  • 05 Jul 2017 Preclinical trials in Neuropathic pain in USA (unspecified route) before July 2017
  • 29 Feb 2016 Preclinical trials in Brain injuries in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top